Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 544-554

  Suaŕez Fueyo, Abel ^a   Rojas, José M ^a   Cariaga, Ariel E ^a   Garciá, Esther ^a   Steiner, Bart H ^b   Barber, Domingo F ^a   Puri, Kamal D ^b   Carrera, Ana C ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b Departamento de Biologia Molecular e Celular Centro Nacional de Biotecnología Consejo Superior de Investigaciones Científicas ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAL 129; GS 9829; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; EFFECTOR CELL; ENZYME INHIBITION; FLOW CYTOMETRY; GENE DELETION; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; IC 50; KIDNEY; LIFE EXTENSION; LYMPHOCYTE COUNT; MACROPHAGE FUNCTION; MACROPHAGE INFILTRATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADENOSINE; ANIMALS; ANTIBODIES, ANTINUCLEAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; IMMUNOGLOBULIN G; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE COUNT; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICROSCOPY, CONFOCAL; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; QUINAZOLINONES; QUINOXALINES; SURVIVAL ANALYSIS; THIAZOLIDINEDIONES;

EID: 84904250196     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400350     Document Type: Article

References (79)

1. Graham, R. R., S. V. Kozyrev, E. C. Baechler, M. V. Reddy, R. M. Plenge, J. W. Bauer, W. A. Ortmann, T. Koeuth, M. F. González-Escribano, B. Pons-Estel, et al. 2006. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of SLE. Nat. Genet. 38: 550-555.
2. Lang, T. J., P. Nguyen, J. C. Papadimitriou, and C. S. Via. 2003. Increased severity of murine lupus in female mice is due to enhanced expansion of pathogenic T cells. J. Immunol. 171: 5795-5801. (Pubitemid 37467195)
3. Borchers, A. T., S. M. Naguwa, Y. Shoenfeld, and M. E. Gershwin. 2010. The geoepidemiology of systemic lupus erythematosus. Autoimmun. Rev. 9: A277-A287.
4. Wentworth, J., and C. Davies. 2009. Systemic lupus erythematosus. Nat. Rev. Drug Discov. 8: 103-104.
5. Chatham, W. W., and R. P. Kimberly. 2001. Treatment of lupus with corticosteroids. Lupus 10: 140-147. (Pubitemid 32410067)
6. Han, B. K., A. M. White, K. H. Dao, D. R. Karp, E. K. Wakeland, and L. S. Davis. 2005. Increased prevalence of activated CD70+CD4+ T cells in the periphery of patients with systemic lupus erythematosus. Lupus 14: 598-606. (Pubitemid 41296996)
7. Vratsanos, G. S., S. Jung, Y. M. Park, and J. Craft. 2001. CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J. Exp. Med. 193: 329-337. (Pubitemid 32524516)
8. Golan, T. D., K. B. Elkon, A. E. Gharavi, and J. G. Krueger. 1992. Enhanced membrane binding of autoantibodies to cultured keratinocytes of SLE patients after ultraviolet B/ultraviolet A irradiation. J. Clin. Invest. 90: 1067-1076.
9. Inghirami, G., J. Simon, J. E. Balow, and G. C. Tsokos. 1988. Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin. Exp. Rheumatol. 6: 269-276.
10. Shlomchik, M. J., J. E. Craft, and M. J. Mamula. 2001. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1: 147-153. (Pubitemid 33741968)
11. D'Cruz, D. P., M. A. Khamashta, and G. R. V. Hughes. 2007. Systemic lupus erythematosus. Lancet 369: 587-596. (Pubitemid 46241445)
12. Kuroiwa, T., and E. G. Lee. 1998. Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Lupus 7: 597-603. (Pubitemid 29008225)
13. Klinman, D. M., and A. D. Steinberg. 1995. Inquiry into murine and human lupus. Immunol. Rev. 144: 157-193.
14. Dai, C., Z. Liu, H. Zhou, and L. Li. 2001. Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. Chin. Med. J. (Engl.) 114: 864-868. (Pubitemid 33611948)
15. Hoffman, R. W. 2004. T cells in the pathogenesis of SLE. Clin. Immunol. 113: 4-13.
16. Tesch, G. H., S. Maifert, A. Schwarting, B. J. Rollins, and V. R. Kelley. 1999. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J. Exp. Med. 190: 1813-1824. (Pubitemid 30013847)
17. Lenda, D. M., E. R. Stanley, and V. R. Kelley. 2004. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. J. Immunol. 173: 4744-4754. (Pubitemid 39280711)
18. Wang, Y., and D. C. Harris. 2011. Macrophages in renal disease. J. Am. Soc. Nephrol. 22: 21-27.
19. Delgado-Vega, A., E. Sánchez, S. Löfgren, C. Castillejo-López, and M. E. Alarcón-Riquelme. 2010. Recent findings on genetics of systemic autoimmune diseases. Curr. Opin. Immunol. 22: 698-705.
20. Krishnan, S., V. G. Warke, M. P. Nambiar, G. C. Tsokos, and D. L. Farber. 2003. The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J. Immunol. 170: 4189-4195. (Pubitemid 36428184)
21. Kong, P. L., J. M. Odegard, F. Bouzahzah, J. Y. Choi, L. D. Eardley, C. E. Zielinski, and J. E. Craft. 2003. Intrinsic T cell defects in systemic auto-immunity. Ann. N. Y. Acad. Sci. 987: 60-67. (Pubitemid 36584007)
22. Crispin, J. C., S. N. Liossis, K. Kis-Toth, L. A. Lieberman, V. C. Kyttaris, Y. T. Juang, and G. C. Tsokos. 2010. Pathogenesis of human systemic lupus erythematosus : recent advances. Trends Mol. Med. 16: 47-57.
23. Xu, L., L. Zhang, Y. Yi, H. K. Kang, and S. K. Datta. 2004. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med. 10: 411-415. (Pubitemid 38508521)
24. Borlado, L. R., C. Redondo, B. Alvarez, C. Jimenez, L. M. Criado, J. Flores, M. A. Marcos, C. Martinez-A, D. Balomenos, and A. C. Carrera. 2000. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation. FASEB J. 14: 895-903. (Pubitemid 30241666)
25. Fruman, D. A., and G. Bismuth. 2009. Fine tuning the immune response with PI3K. Immunol. Rev. 228: 253-272.
26. García, Z., A. Kumar, M. Marqués, I. Cortés, and A. C. Carrera. 2006. Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J. 25: 655-661. (Pubitemid 43292428)
27. Zhang, X., N. Tang, T. J. Hadden, and A. K. Rishi. 2011. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 1813: 1978-1986.
28. Kok, K., B. Geering, and B. Vanhaesebroeck. 2009. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 34: 115-127.
29. Okkenhaug, K., A. Bilancio, G. Farjot, H. Priddle, S. Sancho, E. Peskett, W. Pearce, S. E. Meek, A. Salpekar, M. D. Waterfield, et al. 2002. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031-1034. (Pubitemid 34856039)
30. Ali, K., A. Bilancio, M. Thomas, W. Pearce, A. M. Gilfillan, C. Tkaczyk, N. Kuehn, A. Gray, J. Giddings, E. Peskett, et al. 2004. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 431: 1007-1011. (Pubitemid 39434424)
31. Hirsch, E., V. L. Katanaev, C. Garlanda, O. Azzolino, L. Pirola, L. Silengo, S. Sozzani, A. Mantovani, F. Altruda, and M. P. Wymann. 2000. Central role for G protein-coupled PI3K in inflammation. Science 287: 1049-1053.
32. Alcázar, I., M. Marqués, A. Kumar, E. Hirsch, M. Wymann, A. C. Carrera, and D. F. Barber. 2007. Phosphoinositide 3-kinase gamma participates in T cell receptor-induced cell activation. J. Exp. Med. 204: 2977-2987. (Pubitemid 350179565)
33. Di Cristofano, A., P. Kotsi, Y. F. Peng, C. Cordon-Cardo, K. B. Elkon, and P. P. Pandolfi. 1999. Impaired Fas response and autoimmunity in Pten+/- mice. Science 285: 2122-2125. (Pubitemid 29451429)
34. Barber, D. F., A. Bartolomé, C. Hernandez, J. M. Flores, C. Redondo, C. Fernandez-Arias, M. Camps, T. Rückle, M. K. Schwarz, S. Rodríguez, et al. 2005. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11: 933-935. (Pubitemid 41294437)
35. Barber, D. F., A. Bartolomé, C. Hernandez, J. M. Flores, C. Fernandez-Arias, L. Rodríguez-Borlado, E. Hirsch, M. Wymann, D. Balomenos, and A. C. Carrera. 2006. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J. Immunol. 176: 589-593. (Pubitemid 43023307)
36. Suárez-Fueyo, A., D. F. Barber, J. Martínez-Ara, A. C. Zea-Mendoza, and A. C. Carrera. 2011. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activationinduced T cell death. J. Immunol. 187: 2376-2385.
37. Singer, G. G., A. C. Carrera, A. Marshak-Rothstein, C. Martínez, and A. K. Abbas. 1994. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr. Opin. Immunol. 6: 913-920.
38. Guillou, H., C. Lécureuil, K. E. Anderson, S. Suire, G. J. Ferguson, C. D. Ellson, A. Gray, N. Divecha, P. T. Hawkins, and L. R. Stephens. 2007. Use of the GRP1 PH domain as a tool to measure the relative levels of PtdIns(3,4,5)P3 through a protein-lipid overlay approach. J. Lipid Res. 48: 726-732. (Pubitemid 46397476)
39. Fabian, M. A., W. H. Biggs, III, D. K. Treiber, C. E. Atteridge, M. D. Azimioara, M. G. Benedetti, T. A. Carter, P. Ciceri, P. T. Edeen, M. Floyd, et al. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23: 329-336. (Pubitemid 41094421)
40. Lannutti, B. J., S. A. Meadows, S. E. Herman, A. Kashishian, B. Steiner, A. J. Johnson, J. C. Byrd, J. W. Tyner, M. M. Loriaux, M. Deininger, et al. 2011. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591-604.
41. Manzanero, S. 2012. Generation of mouse bone marrow-derived macrophages. Methods Mol. Biol. 844: 177-181.
42. Hotary, K., X. Y. Li, E. Allen, S. L. Stevens, and S. J. Weiss. 2006. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev. 20: 2673-2686. (Pubitemid 44498378)
43. Camps, M., T. Rückle, H. Ji, V. Ardissone, F. Rintelen, J. Shaw, C. Ferrandi, C. Chabert, C. Gillieron, B. Françon, et al. 2005. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11: 936-943. (Pubitemid 41294438)
44. Gopal, A. K., B. S. Kahl, S. de Vos, N. D. Wagner-Johnston, S. J. Schuster, W. J. Jurczak, I. W. Flinn, C. R. Flowers, P. Martin, A. Viardot, et al. 2014. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370: 1008-1018.
45. Shugg, R. P., A. Thomson, N. Tanabe, A. Kashishian, B. H. Steiner, K. D. Puri, A. Pereverzev, B. J. Lannutti, F. R. Jirik, S. J. Dixon, and S. M. Sims. 2013. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J. Biol. Chem. 288: 35346-35357.
46. Sadhu, C., B. Masinovsky, K. Dick, C. G. Sowell, and D. E. Staunton. 2003. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 170: 2647-2654. (Pubitemid 36245657)
47. Foukas, L. C., M. Claret, W. Pearce, K. Okkenhaug, S. Meek, E. Peskett, S. Sancho, A. J. Smith, D. J. Withers, and B. Vanhaesebroeck. 2006. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441: 366-370. (Pubitemid 44050203)
48. Jia, S., Z. Liu, S. Zhang, P. Liu, L. Zhang, S. H. Lee, J. Zhang, S. Signoretti, M. Loda, T. M. Roberts, and J. J. Zhao. 2008. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454: 776-779.
49. Laffargue, M., R. Calvez, P. Finan, A. Trifilieff, M. Barbier, F. Altruda, E. Hirsch, and M. P. Wymann. 2002. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16: 441-451. (Pubitemid 34260921)
50. Weening, J. J., V. D. D'Agati, M. M. Schwartz, S. V. Seshan, C. E. Alpers, G. B. Appel, J. E. Balow, J. A. Bruijn, T. Cook, F. Ferrario, et al. 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15: 241-250. (Pubitemid 38140764)
51. Crispin, J. C., M. Oukka, G. Bayliss, R. A. Cohen, C. A. Van Beek, I. E. Stillman, V. C. Kyttaris, Y. T. Juang, and G. C. Tsokos. 2008. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181: 8761-8766.
52. Horwitz, D. A. 2008. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res. Ther. 10: 227.
53. Patton, D. T., O. A. Garden, W. P. Pearce, L. E. Clough, C. R. Monk, E. Leung, W. C. Rowan, S. Sancho, L. S. Walker, B. Vanhaesebroeck, and K. Okkenhaug. 2006. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177: 6598-6602. (Pubitemid 44715022)
54. Lee, K. Y., F. D'Acquisto, M. S. Hayden, J. H. Shim, and S. Ghosh. 2005. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 308: 114-118. (Pubitemid 40471010)
55. Chen, C., L. C. Edelstein, and C. Gélinas. 2000. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 20: 2687-2695. (Pubitemid 30183487)
56. Waiczies, S., A. Weber, J. D. Lünemann, O. Aktas, R. Zschenderlein, and F. Zipp. 2002. Elevated Bcl-X(L) levels correlate with T cell survival in multiple sclerosis. J. Neuroimmunol. 126: 213-220. (Pubitemid 34521747)
57. Choi, M. S., M. Holmann, C. J. Atkins, and G. G. Klaus. 1996. Expression of bcl-x during mouse B cell differentiation and following activation by various stimuli. Eur. J. Immunol. 26: 676-682. (Pubitemid 26091399)
58. Soond, D. R., E. Bjørgo, K. Moltu, V. Q. Dale, D. T. Patton, K. M. Torgersen, F. Galleway, B. Twomey, J. Clark, J. S. Gaston, et al. 2010. PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115: 2203-2213.
59. Sanchez-Niño, M. D., A. Benito-Martin, S. Gonçalves, A. B. Sanz, A. C. Ucero, M. C. Izquierdo, A. M. Ramos, S. Berzal, R. Selgas, M. Ruiz-Ortega, et al. 2010. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm. 2010. 10.1155/2010/182958.
60. De Rycke, L., D. Baeten, D. Foell, E. Kruithof, E. M. Veys, J. Roth, and F. De Keyser. 2005. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J. Pathol. 206: 17-27. (Pubitemid 40613430)
61. Berndt, A., S. Miller, O. Williams, D. D. Le, B. T. Houseman, J. I. Pacold, F. Gorrec, W.-C. Hon, Y. Liu, C. Rommel, et al. 2010. The p110d crystal structure uncovers mechanisms for selectivity and potency of novel PI(3)K inhibitors. Nat. Chem. Biol. 6: 117-124.
62. Angulo, I., O. Vadas, F. Garçon, E. Banham-Hall, V. Plagnol, T. R. Leahy, H. Baxendale, T. Coulter, J. Curtis, C. Wu, et al. 2013. Phosphoinositide 3-kinase d gene mutation predisposes to respiratory infection and airway damage. Science 342: 866-871.
63. Lucas, C. L., H. S. Kuehn, F. Zhao, J. E. Niemela, E. K. Deenick, U. Palendira, D. T. Avery, L. Moens, J. L. Cannons, M. Biancalana, et al. 2014. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 15: 88-97.
64. Clayton, E., G. Bardi, S. E. Bell, D. Chantry, C. P. Downes, A. Gray, L. A. Humphries, D. Rawlings, H. Reynolds, E. Vigorito, and M. Turner. 2002. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196: 753-763.
65. Haylock-Jacobs, S., I. Comerford, M. Bunting, E. Kara, S. Townley, M. Klingler-Hoffmann, B. Vanhaesebroeck, K. D. Puri, and S. R. McColl. 2011. PI3Kd drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J. Autoimmun. 36: 278-287.
66. Okkenhaug, K., D. T. Patton, A. Bilancio, F. Garçon, W. C. Rowan, and B. Vanhaesebroeck. 2006. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 177: 5122-5128. (Pubitemid 44527583)
67. Ladygina, N., S. Gottipati, K. Ngo, G. Castro, J. Y. Ma, H. Banie, T. S. Rao, and W. P. Fung-Leung. 2013. PI3K g kinase activity is required for optimal T-cell activation and differentiation. Eur. J. Immunol. 43: 3183-3196.
68. Kshirsagar, S., E. Binder, M. Riedl, G. Wechselberger, E. Steichen, and M. Edelbauer. 2013. Enhanced activity of Akt in Teff cells from children with lupus nephritis is associated with reduced induction of tumor necrosis factor receptor-associated factor 6 and increased OX40 expression. Arthritis Rheum. 65: 2996-3006.
69. Shin, M. S., N. Lee, and I. Kang. 2011. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr. Opin. Rheumatol. 23: 444-448.
70. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664. (Pubitemid 18005583)
71. Janeway, C., P. Travers, M. Walport, and J. Capra. 1999. Immunobiology: The Immune System in Health and Disease. Garland, New York.
72. Nechemia-Arbely, Y., D. Barkan, G. Pizov, A. Shriki, S. Rose-John, E. Galun, and J. H. Axelrod. 2008. IL-6/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 19: 1106-1115.
73. Ji, H., F. Rintelen, C. Waltzinger, D. Bertschy Meier, A. Bilancio, W. Pearce, E. Hirsch, M. P. Wymann, T. Rückle, M. Camps, et al. 2007. Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 110: 2940-2947. (Pubitemid 350006947)
74. Winkler, D. G., K. L. Faia, J. P. DiNitto, J. A. Ali, K. F. White, E. E. Brophy, M. M. Pink, J. L. Proctor, J. Lussier, C. M. Martin, et al. 2013. PI3K-δ and PI3Kγ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20: 1364-1374.
75. Maxwell, M. J., E. Tsantikos, A. M. Kong, B. Vanhaesebroeck, D. M. Tarlinton, and M. L. Hibbs. 2012. Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease. J. Autoimmun. 38: 381-391.
76. Wang, Y., L. Zhang, P. Wei, H. Zhang, and C. Liu. 2014. Inhibition of PI3Kδ improves systemic lupus in mice. Inflammation. 37: 978-983.
77. Menke, J., W. A. Rabacal, K. T. Byrne, Y. Iwata, M. M. Schwartz, E. R. Stanley, A. Schwarting, and V. R. Kelley. 2009. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J. Am. Soc. Nephrol. 20: 2581-2592.
78. Menke, J., Y. Iwata, W. A. Rabacal, R. Basu, E. R. Stanley, and V. R. Kelley. 2011. Distinct roles of CSF-1 isoforms in lupus nephritis. J. Am. Soc. Nephrol. 22: 1821-1833.
79. Chang, Y. S., C. J. Liu, T. H. Wu, C. H. Chaou, K. C. Lin, S. M. Ou, T. J. Chen, W. S. Chen, C. T. Chou, and C. Y. Tsai. 2013. Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: a nationwide population-based study in Taiwan. Rheumatology 52: 166-172.